Scilex Holding Company
NASDAQ:SCLXDrug Manufacturers - General
-$0.17 today
- Market cap
- $53.83M
- Beta
- 1.71
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$60.90
Volume 0.00M
Average 0.13M
SCLX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Scilex Holding CompanyNASDAQ: SCLX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $3.21M rose 30.7% year over year, behind the +138.8% change in trailing-twelve-month research & development. Sequentially, it fell 60.7% from the prior quarter. Over 3 fiscal years it compounded at +31.8% a year.
Context
- Research & development amounted to 68.5% of revenue in FY2025, up 51.4 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +30.7% toward the trailing-twelve-month pace of +138.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 20.71M USD
- Year-over-year change
- +114.8%
- 4-year CAGR
- +22.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.71M | +114.8% |
| FY2024 | 2024-12-31 | 9.64M | -24.4% |
| FY2023 | 2023-12-31 | 12.75M | +40.8% |
| FY2022 | 2022-12-31 | 9.05M | -1.6% |
| FY2021 | 2021-12-31 | 9.2M | — |
Research & Development vs competitors
How SCLX compares with its peers on the latest reported figures
- SCLX's LTM Mar 2026 research & development of $21.46M is the 7th highest of the 9 companies compared; the peer median is $39.93M.
- Its year-over-year change of +138.8% is the highest of 9, against a peer median of -19.2%.
- Research & development amounts to 63.4% of revenue for SCLX, versus a peer median of 190.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $114.68M | -37.7% | -16.4% | 622.7% | |
| LTM Mar 2026 | $96.1M | -9.9% | +48.0% | — | |
| LTM Mar 2026 | $51.51M | -27.2% | -33.9% | — | |
| LTM Mar 2026 | $41.33M | -11.2% | -6.2% | 274.8% | |
| LTM Mar 2026 | $38.53M | -58.1% | — | 31.1% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $33.44M | +11.2% | +29.0% | 279.0% |
| LTM Mar 2026 | $21.46M | +138.8% | +31.8% | 63.4% | |
| LTM Mar 2026 | $5.46M | -7.8% | +691.2% | 106.3% | |
CTORCitius Oncology, Inc. | LTM Mar 2026 | $4.11M | -39.8% | -2.2% | 73.3% |
| Peer median (excluding SCLX) | $39.93M | -19.2% | -2.2% | 190.6% | |
Competitors are the stored peer set for SCLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 31.32M | 38.03M | 46.74M | 56.59M | 30.25M |
| Cost of Revenue | 3.63M | 10.8M | 15.68M | 16.69M | 15.22M |
| Gross Profit | 27.68M | 27.24M | 31.06M | 39.9M | 15.03M |
| Gross Margin | 88.4% | 71.6% | 66.5% | 70.5% | 49.7% |
| Research & Development | 9.2M | 9.05M | 12.75M | 9.64M | 20.71M |
| Selling, General & Admin | 50.58M | 64.9M | 119.64M | 119.02M | 266.63M |
| Operating Expenses | 63.52M | 77.87M | 136.49M | 123.3M | 287.34M |
| Depreciation & Amortization | 3.78M | 4.45M | 4.15M | 4.05M | 4.62M |
| EBITDA | (72.88M) | (9.3M) | (109.1M) | (66.8M) | (357.95M) |
| EBITDA Margin | -232.7% | -24.5% | -233.4% | -118.0% | -1183.2% |
| Operating Income | (35.84M) | (50.63M) | (105.43M) | (83.4M) | (272.3M) |
| Operating Margin | -114.4% | -133.1% | -225.6% | -147.4% | -900.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 11.76M | 9.6M | 1.07M | 1.96M | 11.46M |
| Other Income / Expenses | (52.58M) | 27.27M | (8.89M) | 10.59M | (101.72M) |
| Income Before Tax | (88.42M) | (23.36M) | (114.32M) | (72.81M) | (374.03M) |
| Pre-Tax Margin | -282.3% | -61.4% | -244.6% | -128.7% | -1236.3% |
| Income Tax Expense | 5K | 4K | 13K | (1K) | 26K |
| Net Income | (88.42M) | (23.36M) | (114.33M) | (72.81M) | (358.73M) |
| Net Margin | -282.4% | -61.4% | -244.6% | -128.7% | -1185.8% |
| EPS (Basic) | (23.29) | (6.09) | (44.85) | (19.43) | (36.48) |
| EPS (Diluted) | (23.29) | (6.09) | (44.85) | (19.43) | (36.48) |
| Weighted Avg Shares | 3.8M | 3.83M | 3.72M | 6.95M | 11.03M |
| Weighted Avg Shares (Diluted) | 3.8M | 3.83M | 3.72M | 6.95M | 11.03M |
Scilex Holding Company
NASDAQ:SCLX
Intrinsic Alpha fair value
Locked
Current Price
$6.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.